Mabpharm (HKG:2181) shrank its attributable loss in 2024 by 39% to 127.9 million yuan from the 209.4 million yuan loss in the year-ago period, a Wednesday filing with the Hong Kong bourse said.
Loss per share stood at 0.03 yuan, compared with 0.05 yuan loss per share in 2023.
The biopharmaceutical firm's revenue for the year increased by 196% to 258.2 million yuan from 87.2 million yuan a year prior.
The higher revenue was mainly due to the launch of CMAB009 in the market, higher sales of CMAB007 and CMAB008, and a boost in revenue from the exclusive right for commercialization and contract development and manufacturing agreement of CMAB806.
The firm attributed the shrinking of loss mainly to an increase in gross profit, as well as lower research and development expenses.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。